Evidence map›Paper›PMID 29955901›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2018

Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy.

Shiyong Wu, Guanglei Chang, Lei Gao, Dan Jiang, Liyou Wang, Guoxing Li, Xuexiu Luo, Shu Qin, Xueli Guo, Dongying Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. The mMolecular and cellular biochemistry · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. The role and mechanisms of microvascular damage in the ischemic myocardium.Cellular and molecular life sciences : CMLS · 2023
    Review
  19. Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shiyong WuDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Guanglei ChangDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Lei GaoDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Dan JiangDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Liyou WangDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Guoxing LiDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xuexiu LuoDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Shu QinDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xueli GuoDepartment of Vascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China.
Dongying ZhangDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. zdy202284@126.com.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

the "Advanced" Research Foundation Project of Cardiovascular Health Institute of China Cardiovascular Health Alliance Grant No. ky_2017_07_08the Cardiac Rehabilitation and Metabolic Therapy Research Fund Grant No. ky_2016_12_20the Chinese Medicine Science and Technology Project of Chongqing Health and Family Planning Commission Grant No. ZY201702073the National Natural Science Fund of China Grant No. 81570212the Postgraduate Research and Innovation Project of Chongqing Grant No. CYB15093the Science and Technology Plan Project of Chongqing Yuzhong District Grant No.20140111
6 · The paper itself

Abstract

Trimetazidine (TMZ) has been demonstrated to have protective effects against myocardial ischemia/reperfusion (MI/R) injury. In the present study, we investigated the effects and the underlying mechanisms of TMZ on autophagy during MI/R in vivo and in vitro. In the in vivo study, an animal model of MI/R was induced by coronary occlusion. TMZ (20 mg/kg/day) protected the rat hearts from MI/R-induced heart failure by increasing ejection fraction and fractional shortening and decreasing end-systolic volume, end-diastolic volume, left ventricular (LV) internal diameter at systole, and LV internal diameter at diastole; it alleviated myocardial injury and oxidative stress by decreasing LDH, creatine kinase MB isoenzyme, ROS, and MDA levels and increasing SOD and glutathione peroxidase levels in plasma. TMZ also reduced myocardial infarct size and apoptosis. Moreover, TMZ markedly inhibited MI/R-induced autophagy by decreasing the protein and messenger RNA levels of LC3-II, Beclin1, ATG5, and ATG7 and the number of autophagosomes and by involving the AKT/mTOR pathway. Further, in the in vitro experiments, H9c2 cells were incubated with TMZ (40 μM) to explore the direct effects of TMZ following exposure to hypoxia and reoxygenation (H/R). TMZ increased cell viability and the concentration of intracellular SOD and inhibited H/R-induced cell apoptosis and ROS production. Moreover, TMZ decreased the number of autophagosomes and autophagy-related protein expression; it also upregulated p-AKT and p-mTOR expression. In addition, TMZ augmented Bcl-2 protein expression and diminished Bax protein expression, the Bax/Bcl-2 rate, and cleaved caspase-3 level. However, these effects on H9c2 cells were notably abolished by the PI3K inhibitor LY294002. In conclusion, our results showed that TMZ inhibited I/R-induced excessive autophagy and apoptosis, which was, at least partly, mediated by activating the AKT/mTOR pathway. KEY MESSAGES: TMZ improved cardiac function, alleviated myocardial injury and oxidative stress, and reduced the myocardial infarct area and apoptosis. TMZ inhibited MI/R-induced myocardial autophagy, H/R-induced H9c2 cell apoptosis, and autophagy flux. The effect of TMZ on autophagy was repressed by LY294002. TMZ protected against MI/R injury by inhibiting excessive autophagy via activating the AKT/mTOR pathway.

Indexed as

AnimalsApoptosisAutophagyBiomarkersCell LineCell SurvivalDisease Models, AnimalHeart Function TestsImmunohistochemistryMaleMyocardial Reperfusion InjuryMyocardiumMyocytes, CardiacOxidative StressProtective AgentsProto-Oncogene Proteins c-aktBiomarkersProtective AgentsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTrimetazidineAutophagyH9c2 cellHypoxia/reoxygenationIschemia/reperfusionTrimetazidine

Identifiers

PMID29955901
OpenAlexW2810030038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.